Is DNA a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Ginkgo Bioworks Holdings (DNA) rests on AI, autonomous labs, and Datapoints: Ginkgo's central bet is that AI-driven, robot-run autonomous labs will replace the traditional lab bench. The bear case rests on the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic-biology company built around a horizontal cell-programming platform. Historically it reported in two segments: Cell Engineering, where its automated Foundry labs and Datapoints data service engineer and characterize cells for pharma, agriculture, food, and industrial customers; and Biosecurity, which provided pathogen monitoring and bioinformatics to governments and institutions. Cell Engineering revenue is generated through R&D service fees, its Datapoints biological-data offerings, and design, build, and support fees for its lab-automation (RAC) systems. Ginkgo went public via SPAC in 2021 at a lofty valuation that has since collapsed. Since 2024, the story has been restructuring. Facing a low share price, the company completed a 1-for-40 reverse stock split in August 2024 to regain NYSE listing compliance, and it executed large workforce reductions and cost cuts while targeting adjusted-EBITDA breakeven by the end of 2026. In February 2026 it agreed to sell its non-core Biosecurity business, and that divestiture was completed in the first half of 2026, leaving Ginkgo focused on Cell Engineering and autonomous labs. By mid-2026 the picture is a smaller, more focused, still-unprofitable company. Revenue has continued to shrink as legacy programs wind down, but management is betting on autonomous labs, its Nebula facility, the RAC automation systems, and Datapoints (which built recurring revenue and pharma relationships) as the future growth engine. The thesis is high-risk and hinges on whether AI-driven lab automation can scale into a durable, profitable business.
The bull case for DNA
1. AI, autonomous labs, and Datapoints
Ginkgo's central bet is that AI-driven, robot-run autonomous labs will replace the traditional lab bench. Its Nebula facility is positioned as one of the largest autonomous labs, and its RAC automation systems and Datapoints data-generation service aim to sell both hardware and high-value biological datasets for bio-AI. Datapoints has built recurring revenue and relationships with many large pharma firms. If lab automation and data services scale, they could become a durable, higher-margin engine distinct from the old services model.
2. Cost restructuring toward breakeven
Since 2024 Ginkgo has run an aggressive restructuring: deep workforce reductions, facility consolidation, and operating-expense cuts, all aimed at reaching adjusted-EBITDA breakeven by the end of 2026. Narrowing losses and a smaller cost base are the near-term measures investors watch most closely. The company frames this as building a leaner, more focused business, but the path to sustained profitability still depends on stabilizing revenue, which has kept falling even as costs come down.
3. Focus after the Biosecurity divestiture
In February 2026 Ginkgo agreed to sell its non-core Biosecurity business, completing the divestiture in the first half of 2026. That exit removes a lower-growth government-services segment and sharpens the company around Cell Engineering and autonomous labs. Management presents this as concentrating resources on its highest-conviction opportunity. The trade-off is a narrower revenue base and greater dependence on the automation and data thesis actually working.
4. Platform partnerships and pharma relationships
Ginkgo's value depends on landing and expanding customer programs, from large pharma R&D collaborations to agricultural and industrial partners, plus supplier ties such as its long-running DNA-synthesis relationship with Twist Bioscience. Its Datapoints service already works with a number of top pharmaceutical companies. Growing the number and size of these partnerships, and converting pilots into recurring automation and data contracts, is the mechanism by which the platform is supposed to grow into its costs.
The bear case for DNA
The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding DNA already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on DNA
Too few analysts publish on DNA for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The DNA forecast page covers what coverage does exist.
How is DNA valued? (as of Jul 2026)
Snapshot for DNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): Small and declining; Cell Engineering revenue fell year over year, and recent quarterly revenue dropped sharply versus the prior-year period
- Net loss / adjusted EBITDA: Still loss-making; large GAAP net losses continue, though narrower than before, with adjusted-EBITDA breakeven targeted by end of 2026
- Cash position: Several hundred million dollars in cash and marketable securities, funding operations while the company burns cash under its restructuring plan
- Path to profitability: Management guides to adjusted-EBITDA breakeven by the end of 2026 via cost cuts; sustained GAAP profitability is not yet in sight
- Market cap: A small-cap after the post-SPAC collapse and 1-for-40 reverse split; a fraction of its peak valuation
- Analyst coverage: Limited and cautious; the stock is widely treated as speculative and high-risk rather than a value or income holding
These are qualitative descriptions, not precise figures, and they are tied to the asOf date; verify live numbers before acting. Traditional earnings multiples do not apply to Ginkgo because it is unprofitable, so what matters is the trajectory of revenue, losses, cash burn, and progress toward the stated breakeven target. Because the company is pre-profit and pivoting its model, its valuation reflects belief in a future that has not yet been proven.
How do you decide if DNA is a buy?
Rather than asking whether DNA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold DNA indirectly through an index or sector ETF before adding more.
What would change your mind on DNA
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: AI, autonomous labs, and Datapoints stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the DNA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about DNA against your real portfolio and see your actual exposure before deciding.
Investing in Ginkgo Bioworks Holdings with AI
Connect the broker you already use and ask Walnut's AI how DNA fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is DNA a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on AI, autonomous labs, and Datapoints, with revenue (ttm) at Small and declining; Cell Engineering revenue fell year over year, and recent quarterly revenue dropped sharply versus the prior-year period. The bear case rests on the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell DNA?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for DNA?
+
AI, autonomous labs, and Datapoints. Ginkgo's central bet is that AI-driven, robot-run autonomous labs will replace the traditional lab bench.
What is the bear case for DNA?
+
The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor.
What does Ginkgo Bioworks Holdings do?
+
Ginkgo Bioworks Holdings, Inc.
What would have to change for DNA to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AI, autonomous labs, and Datapoints) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Is DNA a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. Ginkgo is a speculative, unprofitable company with falling revenue and ongoing cash burn, so it is high-risk. The bull case is that its autonomous-lab and Datapoints pivot scales into a profitable business after deep cost cuts; the bear case is continued losses, dilution, and a thesis that never pays off. Weigh both against your portfolio.
What does Ginkgo Bioworks actually do?
+
Ginkgo runs a horizontal cell-programming platform: it uses automated labs, software, and biological data to engineer and characterize cells for pharma, agriculture, food, and industrial customers. It earns money from R&D service fees, its Datapoints data-generation service, and its lab-automation systems. After selling its Biosecurity unit in 2026, it is focused on Cell Engineering and autonomous labs.
Does Ginkgo Bioworks make money?
+
No. Ginkgo is unprofitable and has reported large net losses, and its revenue has been shrinking year over year. Since 2024 it has cut costs aggressively and targets adjusted-EBITDA breakeven by the end of 2026, but that is an adjusted measure and does not mean GAAP profitability. Anyone considering the stock should treat it as a pre-profit, cash-burning company.
Walnut is informational, not investment advice, and gives no verdict on DNA. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.